Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Tandem Diabetes Care (TNDM)

Tandem Diabetes Q4 sales rise 3% to $290.4 million; 2025 net loss widens to $204.7 million

Mixed Impact 4 of 5 earnings Written later

Tandem Diabetes reported fourth-quarter and full-year 2025 results on February 19, 2026, and gave 2026 guidance. Worldwide sales rose 3% in the quarter to $290.4 million and 8% for the year to $1.015 billion, but the full-year GAAP net loss grew to $204.7 million from $96.0 million, including a $75.2 million acquired in-process research and development charge. The company expects 2026 sales of $1.065 billion to $1.085 billion, which would be above 2025 sales.

Key points

  • Q4 2025 GAAP operating income was $8.3 million, compared with an operating loss of $0.6 million a year earlier; Q4 net loss was $0.6 million versus net income of $0.8 million.
  • Full-year 2025 GAAP net loss was $204.7 million, or $3.04 per share, compared with $96.0 million, or $1.47 per share, in 2024.
  • 2026 guidance: sales of $1.065 billion to $1.085 billion, gross margin of 56% to 57%, and adjusted EBITDA margin of 5% to 6%.
  • The company is moving to a pay-as-you-go model in the U.S. pharmacy channel, which the filing says creates a $70 million to $80 million headwind in 2026.

The filing

CompanyTandem Diabetes Care (TNDM)
Form8-K, current report
Filed with the SECFeb 19, 2026, 4:06 PM ET
Accession number0001438133-26-000009

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 19, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.